Around the Practice: Optimizing Patient Referrals for Bispecifics and CAR-T Therapies : Episode 4

Similarities and Differences among Bispecifics: BCMA vs non-BCMA

September 13, 2024

By Samer A. Al'Hadidi, MD
Frits van Rhee, MD, PhD

Opinion

Video

Medical experts examine differences and similarities in the referral process and treatment protocols for non–BCMA-targeted vs BCMA-targeted bispecific therapies, including aspects like step-up dosing and premedication.

EP: 1.Importance of Collaboration between Academic and Community Centers

EP: 2.Referral Process: Streamlining and Challenges Seen

EP: 3.Referral Process: Bispecifics

Now Viewing

EP: 4.Similarities and Differences among Bispecifics: BCMA vs non-BCMA

EP: 5.Types of Referrals and Impact of Social Factors on the Referral Process

EP: 6.Managing AEs Seen with Bispecifics

EP: 7.Referral Process: CAR T-Cell Therapy

EP: 8.CAR T: Impact of Recent Approvals on the Referral Process

EP: 9.Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care

EP: 10.Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMM

Video content above is prompted by the following:

Is the process different/similar for patients who might be receiving non–BCMA-targeted bispecific vs BCMA-targeted bispecific?

Review any differences/similarities between bispecifics (non-BCMA vs BCMA) for step-up dosing, premedication/prophylaxis, etc.